Follow
Di Bei
Di Bei
ACOP, ASCPT, ACCP, AAPS, AACR
Verified email at ufl.edu
Title
Cited by
Cited by
Year
Engineering nanomedicines for improved melanoma therapy: progress and promises
D Bei, J Meng, BBC Youan
Nanomedicine 5 (9), 1385-1399, 2010
1492010
Formulation of dacarbazine-loaded cubosomes—part I: influence of formulation variables
D Bei, J Marszalek, BBC Youan
Aaps PharmScitech 10, 1032-1039, 2009
842009
Formulation of dacarbazine-loaded cubosomes. Part III. Physicochemical characterization
D Bei, T Zhang, JB Murowchick, BBC Youan
AAPS pharmscitech 11, 1243-1249, 2010
662010
Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors
J Shao, SJ Markowitz, D Bei, G An
Journal of Pharmaceutical Sciences 103 (12), 3810-33, 2014
462014
Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC–tandem mass spectrometry
W Chen, D Wang, L Wang, D Bei, J Wang, WA See, SR Mallery, ...
Journal of Chromatography B 908, 39-44, 2012
442012
Formulation of dacarbazine-loaded cubosomes—part II: influence of process parameters
D Bei, J Marszalek, BBC Youan
AAPS PharmSciTech 10, 1040-1047, 2009
432009
SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2
SR I Catlett, U Aras, Y Liu, D Bei, I Girgis, B Murthy, M Honczarenko
Annals of the Rheumatic Diseases 76, 859, 2017
332017
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2
IM Catlett, U Aras, L Hansen, Y Liu, D Bei, IG Girgis, B Murthy
Clinical and Translational Science 16 (1), 151-164, 2023
252023
Pharmacokinetics and tissue distribution of 5,7-dimethoxyflavone in mice following single dose oral administration
D Bei, G An
Journal of Pharmaceutical and Biomedical Analysis 119, 65-70, 2015
202015
Pharmacokinetics and pharmacodynamics of midazolam after intravenous and intramuscular administration in alpacas
TK Aarnes, PR Fry, JAE Hubbell, RM Bednarski, P Lerche, W Chen, D Bei, ...
American journal of veterinary research 74 (2), 294-299, 2013
202013
Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers.
HM Bei D, Osawa M, Uemura S, Ohno T, Gobburu J, Roy A
Cancer Science 2020 (00), 1-8, 2019
11*2019
Quantification of 5,7-dimethoxyflavone in mouse plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application to a pharmacokinetic study
D Bei, G An
Journal of Chromatography B, 11-17, 2014
82014
Quantification of 5,7-Dimethoxyflavone in Mouse Plasma Using Liquid ChromatographyTandem Mass Spectrometry (LC-MS/MS) and Its Application to a Pharmacokinetic Study
D Bei, G An
AAPS, 2014
82014
Determination of chebulagic acid and chebulinic acid and their pharmacokinetics in mouse
D Bei, L Xie, K Lu, K Chan, S Basu, Z Liu
Cancer Research 73 (8), 2013
42013
Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers (vol 111, pg 528, 2020)
D Bei, M Osawa, S Uemura, T Ohno, J Gobburu, A Roy, M Hasegawa
CANCER SCIENCE 112 (5), 2063-2063, 2021
2021
COMPARISON OF PHARMACOKINETICS OF BMS-986165, A TYK2 INHIBITOR, IN JAPANESE AND NON-JAPANESE HEALTHY SUBJECTS.
U Aras, D Bei, B He, Y Ishida, L Hansen, B Murthy, Y Liu, IG Girgis
CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S58-S58, 2018
2018
SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2
MB Catlett I, Aras U, Liu Y, Bei D, Girgis I
Annals Rheumatic Dis 76, 859, 2017
2017
Preparation and characterization of dacarbazine-loaded cubosomes as alternative nanoformulation for melanoma treatment
D Bei
University of Missouri-Kansas City, 2009
2009
Dacarbazine Loaded Cubosome as Potential Nanomedicine for Improved Melanoma Treatment
D Bei, J Murowchick, A Endale, BB Youan
American Association of Pharmaceutical Scientists, AAPS2008-001296, 2008
2008
The system can't perform the operation now. Try again later.
Articles 1–19